Sexually Transmitted Diseases

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.

Small survey from gay and bisexual men (GBM) inquired about their experiences during COVID-19 restrictions, and feedback on PrEP.

In Brazil, a concerted effort of recruiting adolescents was made to go out and talk with them about PrEP.

US residents with HIV have higher rates of mortality than their peers without infection, but the gap is narrowing, a recent study showed.

Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.

The pandemic's effect on in-person care prioritization may have indirectly influenced the rate of screening opportunities in at-risk persons.

New findings from CUSTOMIZE suggest the once-monthly injection therapy was feasibly implemented and generally favored to once-daily tablets.

Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.

A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.

The therapy, developed by Lupin Pharmaceuticals, now includes the treatment of trichomoniasis in adults patients and their partners.

More treatment options and modalities are now available for patients.

CDC report highlights disparities among “racial, ethnic, gender, and sexual” minorities.

The prevalence of this disease in this patient population is much higher than in the general public.

A new cohort assessment evidences a disparity in weight-related outcomes with the ART regimens at 18 months.

A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.

Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.

A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.

Attention to the endemic virus has lessened over years, and screening and prevention access remains limited among the most at-risk groups.

A John Hopkins expert and major study leader details the evolving epidemiology of the virus.

The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.

The U.S. sentinel surveillance program is a project which monitors for antibiotic-resistant gonorrhea.

In testing, fingolimod blocked cell-free and cell-to-cell transmission of HIV, reducing latent virus.